Saudi Heart Association expands the cardiometabolic model to include liver disease
The Saudi Heart Association has proposed a broader clinical framework for a disease process now described as cardiovascular-kidney-liver-metabolic syndrome, or CKLM syndrome. The shift moves liver disease from the periphery of cardiometabolic thinking to the center of a multisystem disorder that already links heart disease, chronic kidney disease, obesity, diabetes, and fatty liver pathology. In practical terms, the statement argues that metabolic injury rarely respects a single organ boundary. It progresses through a network of shared mechanisms that include insulin resistance, inflammation, and fibrosis, with damage in one organ reinforcing decline in another.
This expansion is especially relevant in settings where obesity, diabetes, and steatotic liver disease are common. In Saudi Arabia, the overlap of these conditions creates a dense clinical burden that cannot be managed well through organ-by-organ silos. A patient with worsening hepatic steatosis may also be moving toward atherosclerotic risk, kidney dysfunction, and heart failure, even before any one specialty labels the condition severe enough to dominate the chart. The CKLM concept tries to capture that trajectory earlier and more completely.
Why the liver belongs inside the same disease continuum
The most important biological reason for adding liver disease is straightforward: metabolic dysfunction-associated steatotic liver disease is not an isolated hepatic problem. Fat accumulation in the liver reflects systemic metabolic stress and is tightly linked to insulin resistance, chronic low-grade inflammation, endothelial dysfunction, and fibrotic signaling. Those same pathways accelerate vascular injury and kidney damage. Once fibrosis begins to develop in one organ, the biological conversation across tissues becomes more aggressive, not less.
A single-sentence reality follows from that biology: liver injury is often an early warning sign of wider cardiometabolic failure.
The CKLM framework treats the liver as both a target organ and a contributor to downstream risk. Hepatic steatosis can accompany dyslipidemia, impaired glucose handling, and adipose tissue dysfunction long before overt cirrhosis appears. From a cardiovascular standpoint, that matters because the presence of hepatic disease can signal a more advanced systemic milieu than traditional risk scoring may capture. From a kidney standpoint, it matters because metabolic and inflammatory stressors act on glomerular and vascular structures in parallel. The result is not a simple linear sequence but a feedback loop.
Stage-based care aims to match treatment intensity to multisystem risk
The statement proposes a stage-based framework to support risk stratification and management across the CKLM spectrum. Staging matters because not every patient with obesity, diabetes, or fatty liver disease carries the same short-term risk. Some have early metabolic dysfunction with limited end-organ injury. Others already have established cardiovascular disease, declining kidney function, and hepatic fibrosis. Grouping all of them under one vague metabolic umbrella would flatten those differences and blunt treatment intensity where it is needed most.
Under this model, clinicians would evaluate the degree of disease burden across the heart, kidney, liver, and metabolic domains rather than waiting for a single dominant event to declare the syndrome. That approach fits the biology of progressive fibrosis and chronic inflammation. It also reflects bedside reality: a patient with rising albuminuria and hepatic steatosis may need more urgent intervention than a patient with isolated obesity and preserved organ function, even if both share the same risk factors.
The statement does not present CKLM as a replacement for established disease-specific care. Instead, it extends the cardiometabolic-kidney continuum by formally including hepatic disease. That expansion is meant to sharpen risk assessment, not dilute it. Stage-based care can also help clinicians coordinate priorities across specialties, since the right intervention may be cardiovascular, renal, hepatometabolic, or a combination of all three.
Integrated therapy depends on overlapping benefits across organs
Treatment recommendations in the statement emphasize agents with established cardiovascular, kidney, and metabolic benefits, with emerging support for combination approaches. That therapeutic logic follows the same shared-pathway biology. If one drug improves glycemic control while also reducing cardiovascular events and slowing kidney decline, it becomes more than a glucose-lowering treatment; it becomes a systems-level intervention. The same reasoning applies when multiple agents are layered to target different but connected pathophysiologic processes.
In CKLM syndrome, the liver is not simply a passive bystander waiting for a hepatology referral. The liver participates in insulin resistance, lipid flux, inflammatory signaling, and fibrotic progression, which means the therapeutic target has to be broader than a single organ endpoint. A medication strategy that addresses weight, glycemia, vascular risk, and renal preservation is better aligned with the disease biology than one built around isolated biochemical targets.
A second blunt clinical truth follows: the best time to intervene is before fibrosis becomes fixed.
Saudi clinical practice needs a framework built for overlap
The high prevalence and coexistence of CKLM-related conditions in Saudi Arabia give the statement direct local relevance. A framework that recognizes the liver alongside the heart, kidney, and metabolic system can improve how clinicians identify risk and prioritize follow-up. It also supports multidisciplinary care, which is often the only workable model when a single patient spans several chronic disease domains at once. Endocrinology, cardiology, nephrology, and hepatology all have a role, but none of them can fully manage the syndrome alone.
The consensus process behind the statement relied on a comprehensive, non-systematic literature review and iterative expert discussion. This is important because the proposed syndrome is a conceptual and clinical framework rather than the product of a single prospective trial. The statement’s authors are essentially arguing that current evidence has matured enough to justify a broader model, even if formal validation is still needed.
What the CKLM framework changes at the bedside
For clinicians, the immediate value of CKLM is not semantic. It changes what gets screened, how risk is staged, and how aggressively overlapping disease states are treated. A patient with obesity and type 2 diabetes may already deserve liver assessment, not only because steatotic liver disease is common, but because liver involvement can indicate deeper cardiometabolic injury. Likewise, a patient with chronic kidney disease and fatty liver disease may deserve cardiovascular evaluation sooner than traditional pathways would suggest.
The framework also creates a more coherent language for counseling patients. Instead of presenting obesity, diabetes, dyslipidemia, fatty liver disease, heart disease, and kidney disease as separate chapters, clinicians can explain them as parts of one progressive syndrome. That framing may improve adherence because it better reflects the way patients actually experience chronic disease: as one condition generating another, often over years.
Validation remains necessary. The statement itself calls for further confirmation of the framework in broader clinical use. The central unanswered issue is not whether the liver belongs in the metabolic conversation; the pathophysiology already says it does. The real test is whether CKLM staging and integrated treatment strategies improve outcomes when applied prospectively across routine care.